Trials / Completed
CompletedNCT02829775
A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies
Extension Protocol for Patients With Chronic Myelogenous Leukemia, Malignant Melanoma or Renal Cell Carcinoma That Have Responded to Treatment With Pegylated-Interferon α-2a or Roferon-A® in Prior Clinical Studies
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This open label extension study will give an opportunity to the participants that have responded to the treatment with Pegylated-Interferon Alfa-2a (Pegasys) or Recombinant Interferon Alfa-2a (Roferon-A®) in prior clinical studies NO15753 (NCT00003542) for Renal Cell Carcinoma (RCC), NO15764 (NCT number not available) and NO16006 (NCT02736721) for Chronic Myelogenous Leukemia (CML), and NO16007 (NCT number not available) for Malignant Melanoma (MM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegylated Interferon Alfa-2a | Participants will maintain the same dose they were receiving in the parent protocol. |
| DRUG | Recombinant Interferon Alfa 2a | Participants will maintain the same dose they were receiving in the parent protocol. |
Timeline
- Start date
- 2004-01-01
- Primary completion
- 2008-01-01
- Completion
- 2008-01-01
- First posted
- 2016-07-12
- Last updated
- 2017-01-09
- Results posted
- 2016-11-17
Locations
8 sites across 7 countries: Bulgaria, Canada, India, Russia, Slovakia, South Africa, Spain
Source: ClinicalTrials.gov record NCT02829775. Inclusion in this directory is not an endorsement.